Every year 50,000 people die from infections which are resistant to antibiotics. And this is estimated to increase; by 2050 10 million people will die worldwide from resistant infections.
As an industry we recognise that we all have a role in to play in tackling AMR. We are working internationally and locally to do so.
It's World Antibiotic Awareness Week between 12-18 November, 2018. We'll be sharing our industry's commitment to tackling AMR on Twitter @ABPI_UK and encouraging people to sign up to become Antibiotic Guardians and help keep antibiotics working. Find out more at antibioticguardian.com.
In 2016, over 100 companies and 13 associations (including the ABPI) signed the Davos Declaration to tackle AMR at an international level. The AMR Industry Alliance then laid out a roadmap to deliver these commitments. These commitments mean that there is a global effort being taken by industry to address:
We’re making progress across each of those commitments. The AMR Industry Alliance published a Progress Report in January 2018 showing global industry progress on R&D, access, surveillance and appropriate use, and manufacturing.
One of the greatest challenges facing AMR is the lack of antibiotics in development. This is a result of a failing market which means that investing in new antibiotic research is not sustainable. For example, of the 18 large companies investing in antimicrobials in 1990, by 2013 only 4 remained.
Nevertheless, we are making progress and in 2016 alone, 22 members of the AMR Industry Alliance made investments to address the current and future medical needs that result from AMR to the tune of at least USD 2 billion. This is having results with around 40 antimicrobials targeted against the WHO/CDC priority resistant pathogens in late stage clinical development (phase II onwards).
But we’re at a tipping point, in order to enable further research and development and see a step change in the number of antibiotics in development we need to address the problem and incentivise the market.
The UK is making real progress and is providing global leadership against AMR. We have been working with the Government to address the market failure and have co-created a proposed new economic model which delinks reimbursement from sales volume.
The model should enable new antibiotics effective against the priority resistant pathogens to be reserved under appropriate use and stewardship programmes, while rewarding innovation and ensuring sustained investment in antibiotic R&D.
We’re pleased that the Government have committed to piloting this model. We now need to see this commitment turn into reality without delay.
The Government is currently refreshing the UK AMR Strategy and will publish an update early next year. The UK Government has been a global leader in raising awareness of AMR through the Prime Ministerial commitment from then Prime Minister, David Cameron, leadership from Dame Sally Davies and Lord O’Neill’s Review in 2016.
It is vital that the next Strategy ensures builds on its success in raising awareness of AMR and encourages global measures to address it.
We are calling for the next strategy to: